Related Experiment Videos
Framework for headache management in pediatric patients with stroke and cerebrovascular lesions: A narrative review
Allison C Hyland1,2,3,4, Samuel J Belfer3,4, Christine K Fox1
1Department of Neurology and Weill Institute for Neuroscience, University of California San Francisco, San Francisco, California, USA.
Insights
Managing headaches in pediatric stroke patients requires careful drug selection due to vascular risks. Non-pharmacologic therapies and addressing underlying vascular lesions offer promising, safer options for these complex cases.
Area of Science:
- Neurology
- Pediatric Neurology
- Vascular Neurology
Background:
- Chronic headache is a common complication following ischemic or hemorrhagic stroke in pediatric patients.
- Pediatric patients with cerebrovascular disorders and headaches present unique treatment challenges due to medication vasoactivity.
- Standard headache medications may increase cerebrovascular risk in this vulnerable population.
Purpose of the Study:
- To establish an evidence-based framework for managing headache disorders in pediatric patients with prior stroke or cerebral vascular lesions.
- To evaluate the safety and efficacy of pharmacologic and non-pharmacologic headache therapies in this population.
- To provide guidance on drug selection considering vascular pathophysiology and hemodynamic stability.
Main Methods:
- A comprehensive MEDLINE literature review was conducted, searching for headache medication classes and specific neurovascular conditions.
- Included studies were published in English or translated, dating from 1990, and encompassed various study types (in vitro/in vivo, reviews, case series/reports).
- Extracted data were organized by vascular condition, summarizing preventive and acute interventions based on efficacy, safety, and theoretical risk.
Main Results:
- Vasoconstrictive agents (triptans, ergots) are generally contraindicated due to risks of ischemia or hemorrhage.
- Anti-hypertensive agents (beta-blockers, CCBs, ARBs) are considered safe and may offer vascular benefits.
- Non-pharmacologic therapies, anti-seizure medications, antidepressants, and melatonin show favorable risk-benefit profiles, though data are limited. Interventions targeting vascular lesions often improve headaches.
Conclusions:
- Individualized headache management is crucial for pediatric patients with cerebrovascular disease.
- Drug selection must account for vascular pathophysiology, hemodynamic stability, and collateral flow.
- Further prospective, pediatric- and lesion-specific studies are needed to optimize headache therapies.
Objective:
To present a practical, evidence-based framework for the management of headache disorders in pediatric patients with prior stroke or underlying cerebral vascular lesions, with particular attention to safety and efficacy of pharmacologic and non-pharmacologic therapies.
Background:
Chronic headache is frequent after ischemic or hemorrhagic stroke (reported in 12-57% of patients) and is also common in cerebrovascular disorders. Pediatric patients with these conditions face unique therapeutic challenges because many typical headache medications have vasoactive or blood pressure-modulating effects that may increase cerebrovascular risk.
Methods:
We performed a comprehensive MEDLINE literature review (July 2024) searching combinations of headache medication classes paired with specific neurovascular conditions.
Inclusion Criteria:
English or translated articles since 1990, comprising human and animal in vitro/in vivo studies, narrative reviews, case series/reports. Extracted data were organized by vascular condition, with summary tables of preventive and acute interventions categorized by evidence of efficacy, safety, and theoretical risk.
Results:
Across conditions, vasoconstrictive agents (triptans, ergots) remain generally contraindicated or used with extreme caution in patients with vascular lesions due to risk of ischemia or hemorrhage. Anti-hypertensive agents (β-blockers, calcium channel blockers [CCBs], angiotensin II receptor blockers [ARBs]) are generally safe and may confer additional vascular benefit in post-stroke headache. Calcitonin gene-related peptide (CGRP) -targeting therapies are not formally contraindicated but may impair compensatory vasodilation in flow-dependent vascular lesions. Anti-seizure medications, antidepressants, melatonin, and non-pharmacologic therapies appear to have favorable risk-benefit profiles, although direct data in these populations are limited. Interventions addressing underlying vascular lesions (e.g., arteriovenous fistulas [AVF] embolization, arteriovenous malformations [AVM] or cavernoma resection, pial synangiosis) often lead to headache improvement.
Conclusion:
In pediatric patients with cerebrovascular disease who have headaches, individualized management is essential. Drug selection must incorporate vascular pathophysiology, hemodynamic stability, and collateral flow considerations. More prospective, pediatric-specific and lesion-specific studies are needed to guide optimal headache therapies in this complex population.
Related Concept Videos
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Stroke: Introduction and Types
Ischemic Stroke ll: Pathophysiology
Ischemic Stroke l: Introduction